6,000 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Aquila Investment Management LLC

Aquila Investment Management LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 6,000 shares of the medical instruments supplier's stock, valued at approximately $1,302,000.

A number of other hedge funds also recently added to or reduced their stakes in PODD. Moneta Group Investment Advisors LLC raised its holdings in shares of Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier's stock valued at $382,818,000 after purchasing an additional 1,299,095 shares in the last quarter. Baillie Gifford & Co. acquired a new stake in shares of Insulet in the 4th quarter valued at $263,144,000. Geode Capital Management LLC raised its holdings in shares of Insulet by 55.4% in the 1st quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier's stock valued at $473,166,000 after purchasing an additional 529,926 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier's stock valued at $452,016,000 after purchasing an additional 474,545 shares in the last quarter. Finally, William Blair Investment Management LLC raised its holdings in shares of Insulet by 145.1% in the 3rd quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier's stock valued at $116,894,000 after purchasing an additional 433,884 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Piper Sandler dropped their target price on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Robert W. Baird raised shares of Insulet from a "neutral" rating to an "outperform" rating and increased their target price for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. Stifel Nicolaus increased their target price on shares of Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a research report on Monday, February 5th. Barclays dropped their target price on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating on the stock in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $250.33.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.90% of the company's stock.

Insulet Price Performance

PODD traded down $4.43 during midday trading on Friday, reaching $175.22. 680,529 shares of the company's stock were exchanged, compared to its average volume of 725,251. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The stock has a market capitalization of $12.27 billion, a PE ratio of 60.21, a P/E/G ratio of 3.15 and a beta of 0.98. The business's 50-day moving average price is $176.72 and its 200 day moving average price is $178.83. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to analysts' expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm's quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 earnings per share. As a group, equities analysts anticipate that Insulet Co. will post 3.08 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.